ProfileGDS5678 / 1424449_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 61% 62% 62% 62% 62% 60% 61% 64% 62% 56% 62% 61% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6758861
GSM967853U87-EV human glioblastoma xenograft - Control 23.6495761
GSM967854U87-EV human glioblastoma xenograft - Control 33.6885562
GSM967855U87-EV human glioblastoma xenograft - Control 43.653162
GSM967856U87-EV human glioblastoma xenograft - Control 53.6645262
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7937262
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6972660
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6636361
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.80964
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6678862
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4050556
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6689662
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6796961
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6663662